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ABSTRACT  
Aim: To assess whether performing routinely 2-deoxy-2-
[18F]fluoro-D-glucose PET/CT (18FDG PET/CT) scan 
from the upper thigh to the vertex of skull  is clinically 
relevant. 
Materials and Methods: 3502 (1634 female; mean-age 
60+16) consecutive patients undergoing 18FDG PET/CT 
were retrospectively analyzed. Patients were divided in 10 
groups according to primary malignancy. Chi-square 
analysis was used to assess differences among 
proportions. A p value < 0.05 was considered significant. 
Results: 18FDG PET/CT was positive in head district in 
130/3502 (3,7%) patients. In all patients lesions were 
unknown before PET/CT examination. PET/CT showed 
158 positive brain/head uptake in the 130 patients. The 
158 lesions were localized in: brain (43/158; 27%), bone 
(52/158; 33%), lymph node (1/158; 0,6%), soft tissue 
(55/158; 35%) and other sites (7/158; 4,4%). According to 
each group, patients were positive in the head district in 
1.0% for Gastrointestinal Cancer (7/690), 3.0 % for 
Genitourinary Cancer (3/101), 3.7 % for Haemathologic 
Cancer (59/1590), 2.7 % for Gynaecologic Cancer 
(3/112), 7.8% for Head-Neck-Thyroid and Parathyroid 
Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% 
for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 
7.4% for Sarcoma (2/27), 11.6% for Unknown Primary 
Tumour (14/121). 
Conclusion: Our data show a relatively high incidence of 
brain/head lesion in patients with Unknown Primary 
Tumour.  
 
Keywords: PET/CT; whole-body acquisition; head; 
brain. 
 
I.  INTRODUCTION 
 
 2-deoxy-2-[18F]fluoro-D-glucose Positron 
emission tomography-computed tomography (18FDG 
PET/CT) is an established whole-body imaging technique 
used in clinical oncology practice. Whole-body 18FDG 
PET/CT (FDG-wb-PET/CT) has been used in 
differentiating and characterizing indeterminate lesions, in 
differentiating recurrent disease from therapeutic effects, 
in staging and evaluating the extent of disease, and in 
monitoring therapy in a variety of cancers [1-3]. 
 Usually oncological 18FDG PET/CT scan is 
performed from the upper thigh to the base of skull, taking 
approximately 24-28 minutes, because most of FDG avid 
lesions are expected within this field of view. However, 
the detection of head region metastases may change 
staging and prognosis and thus the management of 
patients. Brain metastases are a relatively common 
complication of cancer and can affect up to 40% of 
patients, depending upon the primary histology, while 
skull metastases are less frequent [4-6]. The efficacy of 
FDG PET in describing cerebral metastases is 
controversial. The sensitivity of FDG PET in revealing 
cerebral metastases in patients with malignancy has been 
reported to vary from 68% to 82% when compared with 
anatomic imaging [4, 7]. This large range of sensitivity 
likely reflects two factors: first, the high level of 
physiologic cerebral FDG uptake which may interfere 
with the identification of them; and second, the inability 
of PET scanner to show lesions smaller than 6-10 mm. 
Therefore, many studies suggest that 18FDG PET/CT is 
suboptimal for the detection of cerebral and skull 
metastases and many centers do not routinely perform 
scanning of the head in whole-body FDG PET/CT scan 
[8-12]. However, 18FDG PET/CT scan including the head 
can discover unknown lesions in this anatomic district [4, 
13-15], infact FDG-wb-PET/CT is the method of choice 
also for malignant head and neck tumors in both primary 
staging and restaging and its use, as a part of the 
therapeutic algorithm, results in a reduced number of 
unnecessary surgical procedures [16]. 18FDG PET/CT 
scan including the head may be relevant since all the main 
cross-sectional anatomical imaging techniques, such as 
CT and MR, are frequently performed not as total body 
examination, lacking the ability to detect and delineate 
intracranial and skull metastases. 
 Therefore, the aim of this study was to assess 
whether performing routinely 18FDG PET/CT scan from 
the upper thigh to the vertex of skull (FDG-wb-PET/CT) 
be clinically relevant,  considering the length of scan time 





 A total of 3502 consecutive patients (1634 
female; mean-age 60+16), undergoing FDG-wb-PET/CT 
scan for oncological purpose from May 2012 to 
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November 2013, were retrospectively analyzed. All 
patients were divided according to their primary 
malignancy localization in 10 groups: Gastrointestinal 
Cancer, Genitourinary Cancer, Haemathologic Cancer, 
Gynaecologic Cancer, Head-Neck-Thyroid and 
Parathyroid Cancer, Breast Cancer, Lung Cancer, 
Sarcoma, Melanoma, Unknown Primary Tumor. 
The present study was performed according to the 
declaration of Helsinki. All patients gave their informed 
consent for PET/CT examination. The present 
retrospective analysis did not require Institutional Review 




 FDG was synthesized using a Mini Trace GE 
cyclotron and CPCU automated chemistry module (Fx-
FDG GE). 18Fluorine as fluoride was produced using a 
proton-neutron reaction on 95% enriched 18oxygen water. 
18Fluorine-FDG was synthesized in the CPCU using the 
modified Hamacher synthesis. The product was delivered 
pure, sterile and in an injectable form. 
Scan acquisition. All patients fasted 8 hours and 
underwent a blood glucose test examination before the 
injection of an average of 370 MBq of 18FDG via a cubital 
vein. None of the patients included in the study had serum 
glucose levels higher than 140 mG/dL. Patients were kept 
quiet and confortable for 60 min after the injection. No 
muscle relaxants were administered. Immediately before 
PET/CT scan acquisition, all patients were asked to empty 
their bladder.  
 Images were obtained on a Discovery LS (GE 
Medical Systems, Milwaukee, USA), an integrated system 
consisting in NXi PET scanner and Light Speed Plus four 
rows MDCT system. 
PET/CT acquisition included a whole body acquisition: in 
supine position, vertex to upper thigh four-slice spiral CT 
scan with acquisition parameters of 140 kv, 80 mAs, 0,5 
s/CT rotation, a pitch of 1.5, performed during normal 
breathing. This was followed by a PET acquisition of the 
same axial range for 4 min per cradle position. Patient’s 
head was locked to minimize head movement during 
imaging. 18FDG PET images were reconstructed with a 
4.5 mm effective thickness. The CT data were used for 
attenuation correction and images were reconstructed 
using a standard iterative algorithm. 
 
Image interpretation. 18FDG-wb-PET/CT images were 
analyzed on a dedicated workstation (XELERIS, GEMS) 
in the coronal, sagittal and transaxial planes as well as 3-
dimensional projections. Interpretation was based on 
evaluation of 18FDG uptake at the tumor site and 
surrounding sites. In particular, distinctly focal uptake 
higher than surrounding non diseased tissues and with a 
SUV max  > 2.5 was considered as malignant, otherwise it 
was considered negative. Two experienced nuclear 
medicine physician, unaware of clinical as well as all 
other pertinent data, analyzed all patient studies. 
 
Statistical analysis. A Chi-square analysis was used to 
assess differences among proportions. A p value < 0.05 




Of the 3502 patients included in the study, 19.7% 
(690/3502) had Gastrointestinal Cancer, 2.8% (101/3502) 
Genitourinary Cancer, 45.4% (1590/3502) Hematologic 
Cancer, 3.2% (112/3502) Gynaecologic Cancer, 9.5% 
(331/3502) Head-Neck-Thyroid-Parathyroid Cancer, 5.7% 
(200/3502) Breast Cancer, 7.7% (271/3502) Lung Cancer, 
1.7% (59/3502) Melanoma, 0.8% (27/3502) Sarcoma and 
3.5% (121/3502) Unknown Primary Tumor. 
 18FDG-wb-PET/CT was positive in head district 
in 130/3502 (3.7%) of our population. None of the 
patients showed symptoms and/or clinical findings 
suggestive of such lesions. In particular, pathological 
uptake of 18FDG in the head district was found in 1.0% of 
Gastrointestinal Cancer patients (7/690), 3.0 % of 
Genitourinary Cancer patients (3/101), 3.7 % of 
Haemathologic Cancer patients (59/1590), 2.7 % of 
Gynaecologic Cancer patients (3/112), 7.8% of Head-
Neck-Thyroid and Parathyroid Cancer patients (26/331), 
3.5% of Breast Cancer patients (7/200), 2.6% of Lung 
Cancer patients (7/271), 3.4% of Melanoma patients 
(2/59), 7.4% of Sarcoma patients (2/27), 11.6% of 
Unknown Primary Tumour patients (14/121) (p< 0.0001) 
(Fig.1).  
 A total of 158 18FDG-wb-PET/CT brain/head 
lesions were observed in the 130 patients. Of these 158 
lesions, 27% (43/158) were cerebral, 33% (52/158) 
involved bone structures, 0.6% (1/158) involved lymph 
nodes, 35% (55/158) were localized in soft tissue and 
4.4% (7/158) had other head location. Table 1 shows head 
lesions according to primary cancer disease. Brain lesions 
were more frequent in patients with lung and breast cancer 
while bone lesions and soft tissue localizations were more 
frequent in gastrointestinal and gynaecologic cancer and 
in haematological disease and melanoma respectively. 
 
Table 1. Number and type of lesions for each cancer 
disease 
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In this study a relatively low frequency (3.7%) of 
head abnormalities at 18FDG-wb-PET/CT was found. This 
finding is in agreement with that of a previous study [4], 
performed using only a PET scanner, suggesting that 
18FDG-PET has a little impact in the investigation of 
cerebral metastases, with 3,9% of abnormal findings in 
head district. 
  However, in a particular subsets of disease, 
Unknown Primary Tumour a somewhat different 
percentage of head lesions (11.5%) was observed. Thus it 
seems to be appropriate to perform PET/CT including the 
whole head in this condition. On the other hand, it has 
been demonstrated that FDG-PET represents an accurate 
and useful test for the work-up of patients with suspected 
or proven intracranial metastases [17].    
 In a previous study [18] it has been recognized 
that among common malignant tumours that metastasize 
to the brain, lung cancer (41,6%), melanoma and breast 
cancer (8,3%) are more frequent. We found that brain 
lesions are more frequent in patients with breast and lung 
cancer as compared with the other neoplastic diseases 
studied. In particular in patients with lung cancer it has 
been demonstrated that there is a difference of metabolism 
in brain metastases from non-small-cell-lung cancer 
(NSCLC) and in those from small cell lung cancer 
(SCLC). One third of brain metastases from lung cancer 
are hypometabolic, but NSCLC was more frequently 
associated with hypermetabolic metastatic brain lesions 
than SCLC [19], in our group of patients we found only 
hypermetabolic lesions but we haven’t the histological 
correlation for each lesion. 
Two studies performed in patients with melanoma showed 
that routine skull base to upper thigh acquisition is 
adequate for this group of patients and in particular PET is 
an extremely useful tool in the detection of metastatic 
melanoma, playing a primary role also in the staging of 
this disease to detect metastic lesions in particular in soft 
tissues [13, 20] as showed also by our study. 
 Kole A.C. et al. [15] showed that 18FDG-PET 
was able to identify the site of unknown primary tumor in 
24% of patients unsuccessful studied by Conventional 
Imaging and in the present study PET was able to identify 
1 brain lesion and 13 cervical lymph nodes, according to 
our results that showed among all types of cancer, 
PET/CT was positive in head district in 11,5% of patients 
with UPT, demonstrating the utility to perform a whole-
body PET/CT including head in this subsets of patients. 
These data are also in agreement with two large meta-
analysis of the performance of 18FDG-PET in the 
detection of Unknown Primary Tumor and they have 
demonstrated that 18FDG-PET could be useful in the 
staging of these patients [21, 22]. In the same way a recent 
study by Sebro et al. demonstrated that although the 
lesions found using a true whole-body FDG PET/CT scan, 
rarely change the stage, might have impact on clinical 
management [23].   
 Our findings demonstrated that soft tissue 
metastases detected with 18FDG-wb-PET/CT are in a 
higher percentage (35%) among all detected lesions. 
These results are quite similar to those of Nguyen NC. et 
al. [24] that concluded showing the detection of soft tissue 
metastases, higher in 18FDG-wb-PET/CT, may have a 
prognostic implications, providing more accessible biopsy 
sites and avoiding invasive procedures. Moreover 
Pfannenberg C. et al.  [25] have demonstrated 18FDG 
PET/CT has higher sensitivity than MRI in detecting skin 
and soft tissue metastases, supporting the increasing role 
of 18FDG PET/CT in cancer patient management.  
 We acknowledge the limitations of our 
retrospective study. First of all we have not a histological 
correlation for each lesion. There are undoubtedly false 
positives findings, because 18FDG uptake and resulting 
increased tracer activity is not limited to neoplastic tissue 
and in the same way 18FDG PET/CT is suboptimal in 
detecting brain metastases due to the intense physiologic 
background uptake in the brain and the hypometabolic 
nature of some brain metastases. In addition 18FDG 
PET/CT from the vertex of skull to the upper thigh 
requires additional several minutes of image acquisition 
and also an additional radiation dose that can be useless 
for the all categories of patients. 
 
 
V.  CONCLUSION 
 
In conclusion our data support the importance of 
the inclusion of head district in the whole body 18FDG 
PET/CT scan only for patients with Unknown Primary 
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Tumor where a faster diagnosis could avoid unnecessary 
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